• 1. O-Glycosylations under neutral or basic conditions
  Knud J. Jensen J. Chem. Soc. Perkin Trans. 1 2002 2219
• 2. The determination of 3,5-dinitrosalicyl-(5-nitrofurfurylidene)hydrazide (nifursol) in animal feeding stuffs by electron-capture gas chromatography
  B. B. Wheals,R. E. Weston Analyst 1971 96 78
• 3. Intramolecular base catalysed hydrolysis of ortho-hydroxyaryl esters: the anomalous position of methyl 3,5-dinitrosalicylate on the Linear Free Energy Relationship plot
  Alexei U. Moozyckine,D. Martin Davies J. Chem. Soc. Perkin Trans. 2 2002 1158
• 4. Efficient synthesis of glycosylated phenazine natural products and analogs with DISAL (methyl 3,5-dinitrosalicylate) glycosyl donors
  Jane B. Laursen,Lars Petersen,Knud J. Jensen,John Nielsen Org. Biomol. Chem. 2003 1 3147
• 5. Participation of o-carboxylate groups in aromatic nucleophilic substitution
  R. Muthukrishnan,R. Kannan,S. Swaminathan J. Chem. Soc. Perkin Trans. 1 1973 2949

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenols Dinitrophenols
• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenols Nitrophenols Dinitrophenols

Methyl 3,5-dinitrosalicylate (CAS No. 22633-33-6): A Comprehensive Overview

Methyl 3,5-dinitrosalicylate, with the chemical formula C?H?N?O? and CAS number 22633-33-6, is a significant compound in the field of organic chemistry and pharmaceutical research. This compound, characterized by its nitro and ester functional groups, has garnered attention due to its versatile applications in synthetic chemistry and potential therapeutic properties.

The structure of Methyl 3,5-dinitrosalicylate consists of a salicylic acid backbone substituted with two nitro groups at the 3rd and 5th positions, further modified by an ester group at the 1st position. This unique structural configuration imparts distinct chemical reactivity and makes it a valuable intermediate in various chemical syntheses. The presence of multiple nitro groups enhances its utility in electrophilic aromatic substitution reactions, making it a preferred choice for researchers exploring novel synthetic pathways.

In recent years, Methyl 3,5-dinitrosalicylate has been extensively studied for its potential applications in medicinal chemistry. The nitro groups in its structure can be selectively reduced to amine functionalities, which are crucial in the synthesis of bioactive molecules. This property has been exploited in the development of novel drug candidates targeting various diseases, including inflammatory disorders and infectious diseases.

One of the most compelling aspects of Methyl 3,5-dinitrosalicylate is its role as a precursor in the synthesis of heterocyclic compounds. Heterocycles are fundamental structures in many pharmaceuticals and agrochemicals due to their biological activity. Researchers have leveraged the reactivity of the nitro groups to introduce diverse functional moieties into the salicylic acid scaffold, leading to the discovery of several promising lead compounds. These efforts have been particularly fruitful in the development of antimicrobial agents and anti-inflammatory drugs.

The compound's stability under various reaction conditions makes it an ideal candidate for multi-step synthetic protocols. Its ability to undergo nucleophilic substitution reactions while maintaining structural integrity has been utilized in the construction of complex molecular architectures. This has opened up new avenues for drug design, allowing chemists to explore intricate molecular frameworks with potential therapeutic benefits.

Recent advancements in computational chemistry have further enhanced the understanding of Methyl 3,5-dinitrosalicylate's reactivity. Molecular modeling studies have provided insights into how the nitro groups influence electronic distributions and interaction with biological targets. These insights have guided experimental design, leading to more efficient synthetic routes and improved yields of target compounds. The integration of experimental data with computational predictions has become a cornerstone in modern drug discovery processes.

The pharmaceutical industry has shown particular interest in Methyl 3,5-dinitrosalicylate due to its potential as an intermediate in producing novel therapeutics. Its structural features allow for modifications that can fine-tune pharmacokinetic properties such as solubility, bioavailability, and metabolic stability. This flexibility has been instrumental in developing drugs with enhanced efficacy and reduced side effects.

Moreover, Methyl 3,5-dinitrosalicylate has found applications beyond pharmaceuticals. In materials science, it serves as a building block for synthesizing polymers with specialized properties. These polymers exhibit unique characteristics such as high thermal stability and chemical resistance, making them suitable for advanced industrial applications.

The environmental impact of using Methyl 3,5-dinitrosalicylate has also been a subject of research. Efforts have been made to develop greener synthetic methods that minimize waste and reduce energy consumption. These initiatives align with global trends toward sustainable chemistry practices, ensuring that the compound's production is both efficient and environmentally friendly.

In conclusion, Methyl 3,5-dinitrosalicylate (CAS No. 22633-33-6) is a multifaceted compound with significant implications in organic synthesis and pharmaceutical research. Its unique structural features and reactivity make it a valuable tool for developing new drugs and materials. As research continues to uncover its potential applications, this compound is poised to play an even greater role in advancing scientific knowledge and technological innovation.

• 22621-41-6(3-Nitrosalicylic Acid Methyl Ester)
• 609-99-4(3,5-Dinitrosalicylic acid)
• 90564-26-4(Benzoicacid, 2-methoxy-3-nitro-, methyl ester)
• 85-38-1(2-hydroxy-3-nitro-benzoic acid)
• 99-42-3(Methyl 4-hydroxy-3-nitrobenzoate)
• 17302-46-4(5-Nitrosalicylic Acid Methyl Ester)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)